Bendamustine Hydrochloride
"Bendamustine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.
| Descriptor ID |
D000069461
|
| MeSH Number(s) |
D02.241.081.114.625 D02.455.526.728.650.103 D03.633.100.103.123
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bendamustine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Bendamustine Hydrochloride".
This graph shows the total number of publications written about "Bendamustine Hydrochloride" by people in this website by year, and whether "Bendamustine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2025 | 1 | 0 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bendamustine Hydrochloride" by people in Profiles.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma. CPT Pharmacometrics Syst Pharmacol. 2025 Oct; 14(10):1562-1574.
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 06 30; 386(26):2482-2494.
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
-
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr?m Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.
-
How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
-
What lies beneath: Cutaneous involvement of mantle cell lymphoma underlying an insect-bite-like reaction. J Cutan Pathol. 2021 Apr; 48(4):563-566.
-
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
-
An unusual case of cutaneous Waldenstr?m macroglobulinemia with the MYD88 L265P mutation. J Cutan Pathol. 2020 Sep; 47(9):850-853.
-
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020 04; 95(4):354-361.